       Document 0996
 DOCN  M9650996
 TI    Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in
       relation to the number of CD4+ T lymphocytes in adults infected with
       human immunodeficiency virus.
 DT    9505
 AU    Kroon FP; van Dissel JT; Labadie J; van Loon AM; van Furth R; Department
       of Infectious Diseases, University Hospital Leiden,; The Netherlands.
 SO    Clin Infect Dis. 1995 Nov;21(5):1197-203. Unique Identifier : AIDSLINE
       MED/96126004
 AB    A prospective study of antibody production by adults infected with human
       immunodeficiency virus (HIV) after vaccination with T
       lymphocyte-dependent diphtheria toxoid, tetanus toxoid, and inactivated
       trivalent poliovirus vaccine was conducted. Individuals were divided
       into three groups according to CD4+ T-lymphocyte count: group 1 had a
       count of < or = 100-300 x 10(6)/L; and group 3, > 300 x 10(6)/L. After
       vaccination, 61%, 70%, and 73% of the individuals in groups 1, 2, and 3,
       respectively, developed protective titers of antibody to diphtheria
       toxin; the mean postvaccination antibody titer of HIV-infected
       individuals was significantly lower than that of healthy controls not
       infected with HIV. Furthermore, the mean titers of antibodies to tetanus
       toxin and poliovirus were significantly lower in HIV-infected
       individuals with CD4+ lymphocyte counts of < 300 x 10(6)/L than in
       controls. Of the HIV-infected vaccinees, 83%-100% were protected against
       tetanus and 78%-100% against polio. We conclude that HIV-infected
       individuals with CD4+ lymphocyte counts of < 300 x 10(6)/L have an
       impaired (secondary) antibody response after receipt of T
       lymphocyte-dependent vaccines.
 DE    Adult  Antibodies, Bacterial/BIOSYNTHESIS/BLOOD  Antibodies,
       Viral/BIOSYNTHESIS/BLOOD  Case-Control Studies  *CD4 Lymphocyte Count
       Diphtheria Toxoid/*IMMUNOLOGY  Female  Human  HIV Infections/*IMMUNOLOGY
       Male  Middle Age  Poliovirus Vaccine/*IMMUNOLOGY  Prospective Studies
       Tetanus Toxoid/*IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

